2524 T3D2483 Glipizide Glipizide is only found in individuals that have used or taken this drug. It is an oral hypoglycemic agent which is rapidly absorbed and completely metabolized. [PubChem]Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. 29094-61-9 3478 C21H27N5O4S 365.126110 White powder. 200-203°C 37.2 mg/L Oral. Gastrointestinal absorption is uniform, rapid, and essentially complete. Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. Hepatic. The major metabolites of glipizide are products of aromatic hydroxylation and have no hypoglycemic activity. A minor metabolite which accounts for less than 2% of a dose, an acetylaminoethyl benzine derivatives, is reported to have 1/10 to 1/3 as much hypoglycemic activity as the parent compound. Route of Elimination: The primary metabolites are inactive hydroxylation products and polar conjugates and are excreted mainly in the urine. Half Life: 2-5 hours The acute oral toxicity was extremely low in all species tested (LD50 greater than 4 g/kg). No indication of carcinogenicity to humans (not listed by IARC). For use as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. The acute oral toxicity was extremely low in all species tested (LD50 greater than 4 g/kg). Overdosage of sulfonylureas including glipizide can produce hypoglycemia. 2009-07-03T22:08:18Z 2026-03-31T18:00:29Z Glipizide 239286 D005913 Glipizide DB01067 true CC1=CN=C(C=N1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1 C21H27N5O4S InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28) ZJJXGWJIGJFDTL-UHFFFAOYSA-N 445.535 445.178375067 Exogenous Solid 1.91 HMDB15200 CHEMBL1073 3359 <p>Suresh Kumar Gidwani, Purushottam Singnurkar, Prashant Kumar Tewari, &#8220;Sustained release pharmaceutical composition containing glipizide and method for producing same.&#8221; U.S. Patent US6270797, issued February, 2000.</p> CHEM002065 DTXSID0040676 NS00009815 N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide